Biovica International AB is a diagnostic center located in Uppsala that specializes in cancer monitoring solutions. The organization is known for its development and provision of the DiviTum TKa test, which is a blood test designed to measure cell proliferation. This test plays a significant role in monitoring cancer progression, thereby supporting oncologists in making informed treatment decisions.
The company emphasizes the importance of enhancing confidence in treatment choices and aims to improve patient outcomes in cancer care. Biovica engages with investors through various events and updates, fostering collaboration and participation in its initiatives. By utilizing innovative technology in cancer diagnostics, Biovica International AB contributes to the ongoing advancements in the field of oncology.